Resources for
healthcare professionals

Support for you

Zogenix is committed to supporting healthcare professionals in the treatment of seizures associated with Dravet syndrome.

The European launch meeting for Fintepla

On the 11th February 2021, healthcare professionals from across Europe were invited to join the live and interactive virtual European launch event for Fintepla. If you missed the event (or attended and want to watch some parts again), here you have the opportunity to view a recording of the session. You can either select specific presentations from the agenda or watch the whole meeting by selecting 'Watch all'.

Key Speakers

Stephen J Farr
Stephen J Farr
President,
Zogenix
Prof. Julia Jacobs
Prof. Julia Jacobs
Director of the Pediatric Epilepsy Program
Alberta Children’s Hospital
Prof. Lieven Lagae
Prof. Lieven Lagae
Head of Paediatric Neurology
University Hospitals of Leuven
Prof. Rima Nabbout
Prof. Rima Nabbout
Professor of Paediatric Neurology,
Necker Enfants Malades University Hospital

Welcome and introduction to Zogenix

Zogenix, an innovative biopharmaceutical company supporting people living with rare diseases

Watch all
49 mins 38 secs
Welcome and introduction to Zogenix - 1 min 49 secs
Stephen J Farr
Chairman's introduction - 54 secs
Prof. Lieven Lagae
An urgent need for effective treatments in Dravet syndrome - 9 mins 55 secs
Prof. Lieven Lagae
Introducing Prof. Rima Nabbout - 19 secs
Prof. Lieven Lagae
Fintepla, a new antiepileptic drug approved for treating Dravet syndrome patients in Europe - 13 mins 40 secs
Prof. Rima Nabbout
Introducing Prof. Julia Jacobs - 27 secs
Prof. Lieven Lagae
Expert advice on the use of Fintepla in routine clinical practice - 11 mins 38 secs
Prof. Julia Jacobs
Questions and answers - 10 mins 56 secs
All

Adverse events should be reported.

Please refer to section 4.8 of the SmPC for national reporting requirements in your country.

Adverse events should also be reported to Zogenix International Limited on +44 (0)800 060 8767 or email medinfo.eu@zogenix.com